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Abstract 
Aggressive behavior and diffuse infiltrative growth are the main features of Glioblastoma 
multiforme (GBM), together with the high degree of resistance and recurrence. Evidence indicate 
that GBM-derived stem cells (GSCs), endowed with unlimited proliferative potential, play a critical 
role in tumor development and maintenance. Among the many signaling pathways involved in 
maintaining GSC stemness, tumorigenic potential, and anti-apoptotic properties, the PDK1/Akt 
pathway is a challenging target to develop new potential agents able to affect GBM resistance to 
chemotherapy. In an effort to find new PDK1/Akt inhibitors, we rationally designed and 
synthesized a small family of 2-oxindole derivatives. Among them, compound 3 inhibited PDK1 
kinase and downstream effectors such as CHK1, GS3K and GS3Kwhich contribute to GCS 
survival. Compound 3 appeared to be a good tool for studying the role of the PDK1/Akt pathway in 
GCS self-renewal and tumorigenicity, and might represent the starting point for the development of 
more potent and focused multi-target therapies for GBM.  
 
Keywords: PDK1 inhibitors; kinase inhibitors; oxindole derivatives; glioblastoma; GBM stem 
cells; multi-target therapy  
 
Highlights: 
 The PI3K/Akt pathway plays a key role in malignant phenotypes of Glioblastoma  
 New OXIDs with different linker in 5-position were designed and synthesized. 
 OXID 3 inhibited PDK1 kinase and downstream effectors like CHK1, GS3K and GS3K 
 Compound 3 inhibited self-renewal and proliferation in GBM-derived stem cells. 
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1. Introduction 
Glioblastoma multiforme (GBM) is the most common and lethal primary malignancy of the central 
nervous system (CNS) with a median survival rate of approximately 14 months [1]. Histologically, 
it is characterized by poorly differentiated astrocytes, atypical nuclei, intense mitotic activity, 
vascular thrombosis, microvascular proliferation and necrosis [2, 3]. Despite of many efforts to 
investigate new therapies, there has been little improvement in survival rate over the last 30 years 
[4]. In addition, evidence indicates that a population of tumor cells, i.e. cancer stem cells (CSCs), 
contributes to cancer recurrence and ultimate failure of the existing therapeutic strategies thus 
delineating GBM as a hierarchically organized entity [5].  
CSCs represent the core of the cancer with great capacity for self-renewal and high level of therapy 
resistance, suggesting that they should be a pivotal therapeutic target in order to achieve a complete 
eradication of the tumor itself. 
As expected, GBM-derived stem cells (GSCs) display selective resistance to several chemo- and 
radio-therapies [6]. In particular, irradiated GBMs express an increased level of the stemness 
marker CD133 compared to non-irradiated ones [7]. The resistance in GSCs may depend on several 
mechanisms, such as a high expression of drug efflux pumps [8] and, more importantly, a high 
DNA repair activity.  
Accumulating experiences with targeted therapies in different tumor types clearly indicate that the 
understanding of the molecular mechanisms of oncogenesis, as well as the correlation of genetic 
and pathological features, are pivotal in designing more effective personalized treatments. The loss 
of regulatory mechanisms is the result of alterations in expression of genes involved in cell cycle 
control, such as proto-oncogenes and tumor suppressor genes [9].  
The PI3K/Akt pathway has been identified as an important oncogenic pathway in the malignant 
phenotype of GBM, because triggers a cascade of downstream signaling events that leads to tumor 
growth, survival, invasion into normal brain, and secretion of angiogenic factors. In addition, 
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greater activation and deregulation of PI3K/Akt components appears to increase cell proliferation 
and inhibit GSCs differentiation, thus contributing to resistance to chemotherapy [10].  
As a consequence, a plethora of new compounds targeting different nodes of this pathway, such as 
PI3K inhibitors [11], have been developed, and specific drugs targeting Akt/mTOR are now in 
Phase I/II of clinical trials, alone or in combination with other chemotherapeutic drugs against 
GBM [12, 13] (Figure 1).  
The increasing understanding of the key role played by PI3K/Akt pathway in resistant cancer 
phenotype prompted us to design and synthesize a small series of 2-oxindole derivatives able to 
inhibit Akt phosphorylation [14] (Figure 1). Noteworthy the oxindole is the central nucleus of 
different PI3K/Akt pathway inhibitors [15-17].  Starting from these results and aiming to widen the 
Structure-Activity Relationships (SAR) of this new class of compounds, this study deals with (a) 
the design and synthesis of new inhibitors of PDK1/Akt pathway, (b) prediction of physicochemical 
and ADME (Absorption, Distribution, Metabolism, Excretion) properties, (c) selection of lead 
compound(s) through a screening assay on AKT (PKB alpha) and “PDK1 Direct kinases”(d) 
characterization of the mechanism of action of selected lead-compound including kinases profiling, 
and antiproliferative activity on different GBM cell lines and finally (e) exploration of the effects 
induced on GSCs proliferation and differentiation.    
Among the compounds synthesized, the oxindole 3 effectively reduces the viability on two different 
human glioblastoma cell lines, ANGMS-CSS [18] and U118MG, which are poorly responsive to 
conventional chemotherapies, such as temozolomide (TMZ). Moreover, compound 3 inhibits GSC 
self-renewal and proliferation, triggering both apoptosis and differentiation of the stem cell 
subpopulation. These findings suggest 3 as a novel tool to sensitize GSCs to traditional 
chemotherapeutic strategies.  
 
2. Results and Discussion 
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2.1. Design and in silico prediction of Pharmacokinetic Properties. This study started from our 
recent findings suggesting that 2-oxindole derivatives (OXIDs) inhibit the PDK1/Akt pathway in 
non-small cell lung cancer (NSCLC) [14]. In order to investigate more deeply this class of 
compounds, we performed a systematic medicinal chemistry optimization through a divergent 
synthetic route in three steps. Recent findings demonstrated that the 2-oxindole nucleus may be 
considered as a valid framework upon which to design new ligands able to target the PI3K/Akt. 
Moreover, the substituent in 5-position seems to play a detrimental role for the affinity against 
different kinases involved in the PI3K/Akt pathway [19]. In particular, the substitution of 3,4-
dimethoxytetrahydroisoquinoline alkylamido side chain of previously synthesized oxindole 
derivatives [14] with a tolylsulfonamido group, led to dual Akt/mTOR inhibitors such as FC85 [19] 
(Figure 1). On these basis, we planned to study more deeply the effects induced by the substituent 
in 5-position on the affinity against PDK1 and Akt kinases. Hence, herein we first explore the 5-
position of OXID-framework by the substitution of 3,4-dimethoxytetrahydroisoquinoline-N-
acetamide side chain of 1-3 with a group showing greater flexibility and conformational freedom 
such as 3,4-dimethoxybenzylamino-N-acetamide moiety (4). Then, we replaced the substituent in 5-
position with an electron-rich linker such as the arylurea- (5-10) and arylmethyleneamino-sulfonyl 
moieties (11-13), or with a lesser hindered group, such as the methanesulphonylamido ones (14-16).  
Since a fast and trustworthy prediction of biological properties is a key factor to accelerate the 
process of drug discovery, we estimated in silico the main numerical and topological indices 
together with the molecular transport properties (i.e. blood brain barrier penetration) by PaDEL 
Descriptor [20] (MW, nHBA, nHBD, nRotB, nRotBt, and LipinskiFailures) and by ChemAxon 
MarvinSketch 6.3.0 (LogP, LogD, TPSA, and pKa) [21]. Moreover, based on aforementioned 
calculated molecular features, a druglikeness central nervous system multiparameter optimization 
(CNS MPO) algorithm recently published by Wager et al. [22] was applied to compounds under 
investigation. The CNS MPO desirability score for CNS drugs should be ≥ 4 on 0-6 scale. 
According to the Lipinski’s rule, molecules with good membrane permeability have LogP ≤ 5, 
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molecular weight ≤ 500, number of hydrogen bond acceptors ≤10, and number of hydrogen bond 
donors ≤5. On the basis of the calculated values (Table 1), we synthesized the designed compounds 
since all molecules seemed to satisfy the Lipinsky’s rule of five [23]. 
 
 
2.2. Synthesis of new OXID-derivatives. The final compounds 1-3 were synthesised as previously 
reported [14, 19] whereas compounds 4-10 were obtained following the synthetic procedure 
illustrated in Scheme 1. The catalytic reduction of 5-nitro-2-oxindole gave the 5-amino-2-oxindole 
17 which was then reacted with 4-(methylthio)phenyl-isocyanate providing the ureido-intermediate 
18. The subsequent Knoevenagel reaction with the appropriate carbaldehydes gave the compounds 
5-7. Oxidation of 5-7 with Oxone® (KHSO5 · 0.5KHSO4 · 0.5K2SO4) in MeOH-THF yielded to 
final products 8-10. The 5-amino-2-oxo-indole 17 was also submitted to a reaction with 
methanesulfonyl chloride affording methansulphonamido intermediate 19, which was reacted with 
thiophene-2-carbaldehyde, (N-methyl)-imidazole-2-carbaldehyde or 1H-imidazole-5-carbaldehyde 
affording compounds 14-16, respectively. Finally, starting from intermediate 21, easily obtained by 
a nucleophilic substitution of the -chloroacetamido-derivative 20 with the 3,4-
dimethoxybenzylamine, the reaction with thiophene-2-carbaldehyde gave the final product 4.  
The arylmethyleneamino-sulfonyl derivatives 11-13 were obtained starting from 2-oxo-indole 22. 
(Scheme 2). Derivative 22 was obtained by a handy and efficient  one-pot reductive cyclization of 
2-nitrophenylacetic acid  with iron and acetic acid [24]. The following reaction with 
chlorosulphonic acid gave the 5-(chlorosulfonyl)indolin-2-one 23 as intermediate which reacted 
with 3,4-dimethoxybenzyamine affording the adduct 24. Finally, the Knoevenagel reaction with the 
appropriate carbaldehyde gave final product 11-13. 
An analysis of NMR spectra allowed us to assign the configuration around the double bond in 3-
position of the OXID core. In particular, the final 3-(1H-imidazole-5-yl)-adducts (3,7,10 and 13) 
exist exclusively as Z-isomers, whereas the OXID-derivatives substituted in 3-position with N-
methyl-imidazol-2-yl moiety (2, 6, 9, 12) preferentially adopt the E-isomeric form [25]. 
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On the contrary, we observed that the 2-thienyl substituted products exist as E/Z mixture even if a 
sharp prevalence of Z-isomer has been observed. 
 
2.3. Pharmacology 
2.3.1. Effects induced on ASPC1 cell viability. For a preliminary evaluation of the cytotoxicity of 
the synthesized compounds 1-16, we decided to use the ASPC1 cells [26]. This human pancreatic 
adenocarcinoma cell line is an appropriate model to study new inhibitors of PI3K-AKT pathway, 
since: i) it is characterized by an aberrant activation of PI3K/Akt pathway and ii) shows high degree 
of resistance to currently available chemotherapeutic drugs [27] and to PI3K inhibitors  [26]. 
All the compounds synthesised (1-16) were tested in triplicate at a concentration of 10 M for 72 h 
(Table 2). The results show that, within the 2-oxindoles displaying the 3,4-
dimethoxytetrahydroisoquinoline alkylamido side chain in 5-position, only compound 3 reduces the 
cell viability to around 68%. The substitution of this moiety with the thiomethylphenylureido- (5-7) 
or with the methylsulphonylphenylureido- groups (8-10) is deleterious for the activity against the 
ASPC1, whereas the replacement with a small electron rich group such as the 
methanesulphonamido group (14-16), affects only slightly the cell viability compared to compound 
3 (ASPC1 cell viability of 68% and 74% for 14 and 16, respectively). On the contrary, the 
replacement of the 3,4-dimethoxytetrahydroisoquinoline-N-acetamide side chain with a substituent 
endowed of a greater flexibility and conformational freedom such as the 3,4-
dimethoxybenzylamino-N-acetamido moiety (4) or with the 3,4-dimethoxyaminosulphonyl group 
(11-13), induces a decrease of the antiproliferative activity (≈85% cell viability). Bearing in mind 
the high resistance to conventional therapy reported for the AsPC1 cell line, the reduction of the 
proliferative activity of around 30% induced by compounds 3, 14 and 16 prompted us to further 
investigate them on PDK1/Akt pathway.   
 
2.3.2. In vitro screening assay on Akt and PDK1 enzymes. Because we focused on the discovery 
of new molecules able to affect the PDK1/Akt pathway, the selected OXID-derivatives 3, 14 and 16 
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were consequently submitted to a screening assay on AKT (PKB alpha) and PDK1 direct kinases 
[28]. Compounds 3, 14 and 16 displayed an appreciable inhibitory activity on PDK1 with IC50 
values in the micromolar (14: IC50= 6.81M) and submicromolar ranges (3 and 16: IC50 = 0.98 and 
0.31M, respectively), whereas no inhibition on the recombinant Akt enzyme was observed. The 
data shows that the replacement of the tetrahydroisoquinoline nucleus in 5-position of the oxindole 
core (3), with the methanesulphonamido chain (16) seems not to affect the PDK1-affinity. On the 
contrary, the substitution of the imidazole in 3-position of 16, with a thiophene (14), dramatically 
reduced the potency of about 7 folds. This let us to speculate that the decrease of potency could 
depend, at least in part, to the existence of 14 as a mixture of E/Z-isomers. 
 
2.3.3. In vitro activity on GBM cell lines.  In order to establish the proof of concept for the 
development of Akt-PDK1 inhibitors for GBM, compound 3 was selected and investigated on two 
different human GBM cell lines (ANGMS-CSS and U118MG). These human cell lines show an 
aberrant activation of PDK1/Akt pathway due to PTEN mutation [18, 29] and  are also characterized 
by a high grade of resistance against TMZ, an alkylating agent widely used to treat GBM. The 
selection of the oxindole 3 as prototype to further investigate in GBM cells has been driven by (a) 
the satisfactory and repeatable effect recorded on ASPC1 cells (Table 2), (b) the predicted ability to 
penetrate the blood–brain barrier (BBB) (Table 1) and (c) the significant cytotoxicity previously 
showed in the A549 cell line, which has been reported to be gefitinib-resistant due to the 
maintenance of an EGFR-independent activity of the PI3K/Akt pathway[14]. Actually, considering 
the in vitro PDK1 inhibitory activity, the antiproliferative activity on ASPC1 cell line and the CNS 
MPO score of 4.2, the oxindole 3 was selected as the best candidate.  
Consequently, the antiproliferative effects induced by 3 derivative on GBM cell lines was also 
assessed. Noteworthy, both ANGM-CSS and U-118MG cell lines showed to be  unresponsive to the 
treatment with 100 M of TMZ for 72 h (data not shown). Compound 3 was tested at different 
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concentrations for 72, 96, 120 and 144 h (Figure 2). Data show that 3 inhibits cell growth in a 
concentration-dependent manner, in both cell lines with GI50 values in the low micromolar range 
(Figure 2). Among the two cell lines, ANGM-CSS appears to be more responsive than U-118MG. 
Treating the cells for 72 h with 3 (10 µM) caused a significant amount of phosphatidylserine 
externalisation, in the absence of 7-AAD binding to DNA (Figure 3A and B), demonstrating that 
the compound induced early and late apoptosis of ANGM-CSS cells. As depicted in Figure 3 
(panels C and D) compound 3 induced cell cycle disturbance, strongly arresting cell-cycle in the 
G0-G1 phase. 
The significant reduction of cell viability and the proapoptotic effect of 3 in both resistance cell 
lines suggest a possible contribution of “off-target” activities.  Indeed, PDK1 inhibition has been 
proposed as a highly effective mechanism for reducing metastasis propagation, but also as an 
unable mechanism, at least as selective PDK1 inhibitor, in reducing proliferation in cancer cells 
characterized by an aberrant PI3K/PDK1/AKT expression [30]. Therefore, to elucidate the 
mechanism of action of OXID-derivative 3, a screening profile on 60 kinases involved in the 
PI3K/Akt/mTOR pathway was performed. 
2.3.4. SelectScreen kinase profiling. The study was carried out by SelectScreen Kinase Profiling 
Service, Invitrogen-Life Technologies. Among almost 60 protein kinases screened, compound 3 (1 
M) showed a high inhibitory activity towards GSK3 beta (70% inhibition), a significant activity 
towards GSK3 alpha and CHK1 (59% and 61%, respectively)  (Table S1 Supporting Information) 
and a low activity towards ABL1 (55%). Compound 3 modestly inhibited (< 45%) any of all the 
other tested kinases, including members of both the PKC family (i.e AMPK) and the MAPK family 
(i.e. ERK, JNK). These data indicate that 3 inhibits PDK1 with IC50 980 nM and that, at this 
concentration (1 M) it possesses also a high inhibitory activity towards CHK1 and GSK3A and 
GSK3B, exhibiting IC50 values in the micromolar/submicromolar (Table 3). These data revealed 
that OXID-derivative 3 is a novel focused multi-target PDK1/Akt pathway inhibitor.  
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2.3.5. Effects of 3 on GSC proliferation. Recent evidences demonstrate that GSK-3 inhibition can 
inhibit proliferation and induce differentiation of GSCs [31]; moreover, a combined PDK1 and 
CHK1 inhibition has been reported to play a pivotal role in GSC apoptosis [32]. These findings 
suggest that the simultaneous inhibition of GSK-3, PDK1 and CHK1 may deplete the GBM stem 
cell reservoir. Accordingly, 3 was characterized on GSCs, isolated from glioblastoma ANGM-CSS 
cells as previously reported [19, 33]. 
The OXID-compound induced a time-dependent inhibition of GSC proliferation (Figure 4). 
Moreover, the anti-proliferative effects appeared to be concentration-dependent, with an IC50 value 
of 530 ± 48 nM after 7 days of incubation (Figure 4).  
 
2.3.6. Effects of 3 on GSC apoptosis and cell cycle block. We then investigated whether the 
reduction of GSC proliferation elicited by 3 could be associated to apoptosis. Treating GSC with 3 
for 7 days caused a significant phosphatidylserine externalization in the absence of 7-amino-
actinomysin binding to DNA, thus denoting the induction of early apoptosis (Figure 5). In addition, 
cell cycle analysis demonstrated that challenging GSCs for 7 days with 3 induced a slight cell cycle 
disturbance, arresting cell-cycle progression in the G2-M phase (Figure 5), consistent with a CHK1 
inhibition. [19] 
 
2.3.7. Effects of 3 on morphology and differentiation of GSCs. The effect of 3 on GSC 
morphology was evaluated quantifying the area occupied by the cells in culture plates, as well as 
the outgrowth of cellular processes. Representative photographs of control and treated cells are 
shown in Figure 6. Compound 3 reduced the area occupied by the floating spheres after 7 days of 
GSC treatment, and led to a prominent outgrowth of cellular processes (Figure 6), suggesting that 
the compound could also induce GSC differentiation. To confirm this hypothesis, the levels of stem 
and differentiation markers upon stimulation with 3 were assessed by Real Time RT-PCR analysis. 
In GSCs treated with 3 a significant decrease in the stemness markers, CD133 and Nestin, was 
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noticed, accompanied by a significant increase of Olig, MAP2 and GFAP content. These data 
demonstrate that the compound was able to promote GSC differentiation toward a neuronal and a 
glial phenotype. Comparing the morphological analysis and RT-PCR data indicated that the 
compound triggered both apoptosis and differentiation of GSCs.  
 
2.3.8. Effects of 3 on the formation of GSCs. Next, on the light of GSK3's role in GSC self-
renewal [31], the ability of 3 to affect the formation of GSCs was examined. To this purpose, 
adherent ANGM-CSS cells were switched to a defined serum-free NSC medium, and cells were 
allowed to growth for 9 days, in the absence or in the presence of 3. As depicted in Figure 7, 3 
reduced the number and the diameter of newly generated neurospheres. These results confirmed the 
importance of GSK3 not only in the maintenance of cancer stem profile, but also in their 
transformation process.  
 
3. Conclusion 
Since the aberrant activation of the PDK1/Akt pathway has been reported as a pivotal player in 
many cancer types as well as in the stem cell subpopulation, the possibility to develop new 
molecules that target different steps involved in (and/or downstream of) this signaling system, 
represents a novel strategy to improve the treatment outcome.  
The compelling need to develop new and more effective therapies for the treatment of unresponsive 
tumours such as GBM, prompted us to design and synthesized new inhibitors of PDK1/Akt 
pathway. Recent findings demonstrated that 2-oxindole nucleus may be considered as a good 
starting point to be optimized in order to obtain new targeted ligands. Hence, in this paper we 
described the synthesis and the in vitro evaluation of a small family of OXID-derivatives (1-16). 
Among the new compounds, 3 showed to be a good candidate to further investigate in 
chemoresistant GBM cell lines, because it proved to have: i) a CNS MPO score ≥ 4 (requirement 
for CNS drugs); ii) a significant cytotoxicity against a high resistant cell line (ASPC1), in which the 
12 
 
pathway is aberrantly expressed, and iii) it inhibited PDK1 kinase, as well as some downstream 
effectors such as CHK1, GS3K and GS3K
Aiming at establish the proof of concept for the development of Akt-PDK1 inhibitors for GBM, 
compound 3 was investigated on different human glioblastoma cell lines: ANGMS-CSS and 
U118MG. Results showed that compound 3 proved to induce a concentration-dependent inhibition 
of cell growth in both cell lines, even if ANGM-CSS appears to be more responsive than U-
118MG.  Therefore, considering the significant antiproliferative effect of compound 3 (GI50= 
7.73M in ANGCSS and GI50=14.6 M at 72h U118MG) with respect to TMZ on both cell lines, 
we hypothesized that the whole cytotoxic effects resulted from a synergic inhibition of other 
upstream and/or downstream effectors of PDK1 enzyme. In order to validate such hypothesis and to 
determine the mechanism responsible for the higher activity on GBM cell lines, a kinase profiling 
assay has been performed. 
Most importantly, 3 inhibited GSC self-renewal and proliferation , confirming that a combined 
inhibition of PDK1 and CHK1 can represent an effective therapeutic approach to reduce the growth 
of human GBM [32]. Moreover, OXID 3 promoted GSC differentiation toward a neuronal and a 
glial phenotype. This effect could be due, at least in part to the inhibition GSK3 [31].  
In the whole, compound 3 appears to be a good tool to inhibit GBM proceeding, also inducing stem 
cell differentiation, by the inhibition of PDK1/Akt pathway involved in promoting tumor growth 
and thus contributing to anticancer therapy resistance [19]. The OXID-derivative 3 could mark the 
first step towards the development of new focused multi-target inhibitors useful in countering the 
proliferation of GBM cell lines and of their stem cell subpopulation. 
 
4. Experimental Procedures 
4.1. Chemistry 
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Chemical shifts (δ) are reported in parts per million downfield from tetramethylsilane and 
referenced from solvent references. Coupling constants (J) are given in Hz. 1H NMR and 13C NMR 
spectra of all compounds were obtained with a Varian Gemini 200 spectrometer operating at 200 
MHz or Bruker TopSpin 3.2 spectrometer operating at 400 MHz, in a ~2% solution of DMSO-d6, 
unless otherwise stated. The >95% purity of tested compounds was confirmed by combustion 
analysis. Reactions were followed by thin-layer chromatography (TLC) on Merck aluminum silica 
gel (60 F254) sheets that were visualized under a UV lamp. Melting points were determined on a 
Kofler hot-stage apparatus and are uncorrected. The elemental compositions of the compounds (C, 
H, N) agreed to within (±) 0.4% of the theoretical values. When the elemental analysis is not 
included, compounds were used in the next step without further purification.  Evaporation was 
performed in vacuo (rotating evaporator). Sodium sulfate was always used as the drying agent. 
Celite® 545 was used as filter agent. Commercially available chemicals were purchased from 
Sigma-Aldrich. Compounds 1-3 were synthesized as previously reported [14]. 
4.2. Procedure for the synthesis of final compounds 4-7. To a solution of 5-substituted-2-oxoindole 
(0.39 mmol) in EtOH (7 mL) was added the appropriate carbaldehyde (0.43 mmol) and a catalytic 
amount of piperidine. The resulting solution was stirred and refluxed for 12 h, then the solution was 
evaporated to dryness.  
4.2.1. (3Z)-2-((3,4-dimethoxybenzyl)amino)-N-(2-oxo-3-(thiophen-2-ylmethylene) indolin-5-
yl)acetamide (4). The residual material was purified by crystallization from AcOEt/n-hexane, 
affording 4 as the Z-isomer (36 mg, 0.08 mmol, 20% yield): mp 167-169°C. 1H NMR (CDCl3): δ 
3.37 (dd, 1H, J = 1.8; 15.1 Hz, CH2); 3.55 (d, 1H, J = 12.9 Hz, CH2); 3.75 (d, 1H, J = 15.1 Hz, 
CH2); 3.86 (s, 3H, OMe); 3.89 (s, 3H, OMe); 4.00 (d, 1H, J =12.9 Hz, CH2); 6.66 (d, 1H, J = 8.2 
Hz, Ar); 6.79-6.96 (m, 3H, Ar); 7.11 (dd, 1H, J = 3.6, 5.1 Hz, Ar); 7.32-7.35 (m, 1H, Ar); 7.58 (s, 
1H, H-vinyl); 7.62 (d, 1H, J = 5.1 Hz); 7.76 (d, 1H, J = 3.6 Hz, Ar); 8.00 (s, 1H, Ar) ppm. 13C NMR 
(CDCl3): δ 169.84, 167.85, 148.76, 148.14, 141.84, 137.67, 137.03, 133.48, 128.95, 128.94, 
128.93, 128.16, 126.94, 126.09, 124.97, 120.22, 116.49, 111.23, 110.63, 109.22, 78.63, 55.49, 
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54.44 ppm. Anal. (C24H23N3O4S) Calc%: C 64.13, H 5.16, N 9.35, S 7.13. Found%: C 64.25, H 
5.27, N 9.58, S 7.25. 
 4.2.2. (Z)-N-(4-(methylthio)phenyl)-N’-(2-oxo-3-(thiophen-2-ylmethylene)indolin-5-yl)urea (5). 
The residual material was purified by crystallization from EtOH, affording 5 as the Z-isomer (94 
mg, 0.23 mmol, 60% yield): mp 246-248C. 1H NMR: δ 2.44 (s, 3H, SMe); 6.78 (d, 1H, J = 8.2 Hz, 
Ar); 7.11 (d, 1H, J = 8.2 Hz, Ar); 7.22 (d, 2H, J = 8.4 Hz, Ar); 7.44 (d, 2H, J = 8.4 Hz, Ar); 7.84-
7.92 (m, 3H, Ar, H-vinyl); 7.96-8.01 (m, 1H, Ar); 8.03 (s, 1H, Ar); 8.48 (br s, 1H); 8.68 (br s, 1H); 
10.49 (br s, 1H, NH) ppm. 13C NMR: δ 167.16, 152.65, 137.53, 137.11, 135.69, 133.93, 133.16, 
129.54, 127.81, 127.16, 124.93, 121.87, 120.71, 119.91, 118.78, 111.17, 110.27, 109.27, 16.10 
ppm. Anal. (C21H17N3O2S2) Calc%: C 61.89, H 4.20, N 10.31, S 15.74. Found%: C 61.74, H 4.27, 
N 10.02, S 15.55.  
4.2.3. (3E)-N-(4-(methylthio)phenyl)-N’-(2-oxo-(3-(1-methyl-1H-imidazol-2-yl)methylene)-indolin-
5-yl)urea (6). The residual material was purified by crystallization from EtOH, affording 6 as the E-
isomer (101 mg, 0.25 mmol, 64% yield): mp 235-237°C. 1H NMR: δ 2.43 (s, 3H, SMe); 3.90 (s, 
3H, NMe); 6.78 (d, 1H, J = 8.3 Hz, Ar); 7.21 (d, 2H, J = 8.8 Hz, Ar); 7.36 (s, 2H, Ar); 7.42 (d, 2H, 
J = 8.8 Hz, Ar); 7.53 (s, 1H, H-vinyl); 7.65 (dd, 1H, J = 2.0, 8.3 Hz, Ar); 8.49 (br s, 1H); 8.64 (br s, 
1H); 9.12 (d, 1H, J = 2.0 Hz, Ar); 10.47 (br s, 1H, NH) ppm. 13C NMR: δ 168.27, 157.45, 140.26, 
139.14, 137.00, 138.86, 133.66, 130.76, 129.42, 128.27, 127.52, 123.70, 122.84, 121.55, 119.78, 
112.57, 108.97; 34.25, 14.20 ppm. Anal. (C21H19N5O2S) Calc%: C 62.21, H 4.72, N 17.27, S 7.91. 
Found%: C 62.35, H 4.89, N 17.03, S 8.03.  
4.2.4. (3Z)-N-(4-(methylthio)phenyl)-N’-(2-oxo-(3-(1H-imidazol-5-yl)methylene)indolin-5-yl)urea 
(7). The residual material was purified by crystallization from EtOH, affording 7 as the Z-isomer 
(98 mg, 0.25 mmol, 63% yield): mp 215-217°C. 1H NMR: δ 2.44 (s, 3H, SMe); 6.82 (d, 1H, J = 8.3 
Hz, Ar); 7.12 (dd, 1H, J = 1.3, 8.3 Hz, Ar); 7.22 (d, 2H, J = 8.6 Hz, Ar); 7.44 (d, 2H, J = 8.6 Hz, 
Ar); 7.71 (s, 1H, H-vinyl); 7.79 (s, 1H, Ar); 7.86 (d, 1H, J = 1.3 Hz, Ar); 8.02 (s, 1H, Ar); 8.54 (br 
s, 1H); 8.70 (br s, 1H); 10.90 (br s, 1H, NH) ppm. 13C NMR: δ 167.58, 153.00, 138.60, 137.01, 
15 
 
135.82, 134.00, 133.27, 128.54, 127.41, 127.03 124.93, 122.07, 120.49, 120.01, 118.58, 111.35, 
109.15; 17.18 ppm. Anal. (C20H17N5O2S) Calc%: C 61.37, H 4.38, N 17.89, S 8.19. Found%: C 
61.45, H 4.30, N 18.01, S 8.23.  
4.3. General Procedure for the synthesis of compounds 8-10. A solution of oxone (215 mg, 0.35 
mmol) in water was added to a cooled (0°C) solution of the appropriate derivative 8-10 (0.29 mmol) 
in 1:1 MeOH-THF (2 mL). The resulting mixture was stirred at room temperature for 12 h. Then 
the solid was filtered off, and the solution was evaporated. The residual material was diluted with 
MeOH and the solid product was separated out from the mixture. It was filtered, washed with Et2O, 
and air dried. 
4.3.1. (3Z)-N-(4-(methylsulfonyl)phenyl)-N’-(2-oxo-3-(thiophen-2-ylmethylene)indolin-5-yl)urea (8) 
(76 mg, 0.17 mmol, 60 % yield): mp 213-215°C. 1H NMR: δ 3.16 (s, 3H, SMe); 6.79 (d, 1H, J = 8.3 
Hz, Ar); 7.14 (d, 1H, J = 8.3 Hz, Ar); 7.23 (t, 1H, J = 4.3 Hz, Ar);  7.60-7.92 (m, 6H, Ar); 7.98-8.10 
(m, 2H, Ar, H-vinyl); 8.75 (br s, 1H); 9.29 (br s, 1H); 10.52 (br s, 1H, NH) ppm. 13C NMR: δ 
168.40, 152.56, 148.00, 137.71, 136.09, 134.12, 133.18, 129.54, 127.75, 127.14, 125.03, 121.87, 
120.98, 118.94, 118.75, 111.17, 110.27, 109.27; 52.70 ppm. Anal. (C21H17N3O4S2) Calc%: C 57.39, 
H 3.90, N 9.56, S 14.59. Found%: C 57.54, H 4.01, N 10.10, S 14.78.  
 4.3.2. (3E)-N-(4-(methylsulfonyl)phenyl)-N’-(2-oxo-3-((1-methyl-1H-imidazol-2-
yl)methylene)indolin-5-yl)urea (9) (79 mg, 0.18 mmol, 62% yield): mp 229-231°C. 1H NMR: δ 3.15 
(s, 3H, SMe); 3.90 (s, 3H, NMe); 6.81 (d, 1H, J = 8.2 Hz, Ar); 7.37 (s, 2H, Ar); 7.53 (s, 1H, H-
vinyl); 7.61-7.71 (m, 3H, Ar); 7.81 (d, 2H, J = 8.8 Hz, Ar); 8.70 (br s, 1H); 9.10-9.18 (m, 2H, Ar, 
NH); 10.51 (br s, 1H, NH) ppm. 13C NMR: δ 168.15, 153.45, 143.56, 139.24, 138.50, 137.86, 
134.56, 130.17, 129.71, 128.05, 127.52, 122.73, 122.19, 121.55, 119.53, 112.17, 109.04; 54.25, 
35.20 ppm. Anal. (C21H19N5O4S) Calc%: C 57.66, H 4.38, N 16.01, S 7.33. Found%: C 57.55, H 
4.42, N 16.25, S 7.02.  
 4.3.3. (3Z)-N-(4-(methylsulfonyl)phenyl)-N’-(2-oxo-3-((1H-imidazol-5-yl)methylene)indolin-5-
yl)urea (10) (75 mg, 0.18 mmol, 61% yield): mp 215-217°C. 1H NMR:δ 3.16 (s, 3H, SMe); 6.84 (d, 
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1H, J = 8.2 Hz, Ar); 7.15 (d, 1H, J = 8.3 Hz, Ar); 7.62-7.85 (m, 6H, H-vinyl, Ar);  7.89 (s, 1H, Ar); 
8.02 (s, 1H, Ar); 8.74 (br s, 1H); 9.24 (br s, 1H); 10.93 (br s, 1H, NH) ppm. 13C NMR: δ 168.85, 
152.25, 144.49, 139.28, 138.46, 135.20, 133.22, 132.82, 128.01, 127.68 124.50, 122.70, 120.11, 
119.45, 117.41, 110.91, 109.73; 55.89 ppm. Anal. (C20H17N5O4S) Calc%: C 56.73, H 4.05, N 16.54, 
S 7.57. Found%: C 57.04, H 4.28, N 16.77, S 7.78.  
4.4. Procedure for the synthesis of final compounds 11-16. Compounds 11-16 were synthesized 
from the appropriate 5-substituted-2-oxoindole (0.39 mmol) in EtOH (7 mL) following the same 
procedure described above for the preparation of  compounds 4-7. 
4.4.1. (3Z)-N-(3,4-dimethoxybenzyl)-2-oxo-3-(thiophen-2-ylmethylene)indoline-5-sulfonamide (11). 
The residual material was purified by crystallization from EtOH, affording 11 as the Z-isomer (110 
mg, 0.24 mmol, 62% yield): mp 246-248°C. 1H NMR: δ 3.62 (s, 6H, OMe); 3.96 (s, 2H, CH2); 
6.68-6.82 (m, 3H, Ar); 6.90 (d, 1H, J = 8.1 Hz, Ar); 7.27 (t, 1H, J = 4.2 Hz, Ar); 7.62 (d, 1H, J = 8.1 
Hz, Ar); 7.82-7.94 (m, 1H, Ar); 7.82-7.84 (m, 2H, Ar, NH); 8.04 (s, 1H, H-vinyl); 8.31 (s, 1H, Ar); 
10.99 (br s, 1H) ppm. 13C NMR: δ 167.23, 148.39, 147.77, 143.00, 138.66, 137.10, 135.39, 133.36, 
130.38, 129.74, 127.65, 127.08, 124.41, 121.53, 119.82, 118.09, 117.69, 111.31, 109.26; 55.40; 
55.20; 46.18 ppm. Anal. (C22H20N2O5S2) Calc%: C 57.88, H 4.42, N 6.24, S 14.05. Found%: C 
58.10, H 4.40, N 6.08, S 14.23. 
 
4.4.2. (3E)-N-(3,4-dimethoxybenzyl)-3-((1-methyl-1H-imidazol-2yl)methylene)-2- oxoindoline-5-
sulfonamide  (12). The residual material was purified by crystallization from EtOH, affording 12 as 
the E-isomer (109 mg, 0.24 mmol, 61% yield): mp 235-237°C. 1H NMR: δ 3.59 (s, 3H, OMe); 3.67 
(s, 3H, OMe); 3.92 (s, 3H, Me); 3.98 (d, 2H, J = 6.1 Hz, CH2); 6.68-6.82 (m, 3H, Ar); 6.96 (d, 1H, 
J = 8.2 Hz, Ar); 7.39 (s, 1H, Ar); 7.46 (s, 1H, Ar); 7.56 (s, 1H, H-vinyl); 7.68 (dd, 1H, J = 1.8, 8.2 
Hz, Ar); 7.92 (br t, 1H, J = 6.1 Hz); 9.92 (d, 1H, J = 1.8 Hz, Ar); 10.99 (br s, 1H) ppm. 13C NMR: δ 
169.27, 148.39, 147.77, 145.27, 142.14, 133.73, 130.60, 130.01, 128.59, 125.72, 123.84, 121.53, 
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119.69, 119.36, 111.57, 108.93; 55.49; 55.18; 46.04; 33.20 ppm. Anal. (C22H22N4O5S) Calc%: C 
58.14, H 4.88, N 12.33, S 7.06. Found%: C 58.02, H 5.16, N 12.06, S 7.30. 
 
4.4.3. (3Z)-3-(1-(1H-imidazol-5-yl)-ethylidene)-N-(3,4-dimethoxybenzyl)-2-oxoindoline-5-
sulfonamide (13). The residual material was purified by crystallization from EtOH, affording 13 as 
the Z-isomer (110 mg, 0.25 mmol, 64% yield): mp 315-320°C. 1H NMR: δ 3.34 (s, 6H, OMe); 3.98 
(d, 2H, J = 8.1 Hz, CH2); 6.68-6.80 (m, 3H, Ar); 7.02 (d, 1H, J = 8.0 Hz, Ar); 7.40 (s, 1H, Ar); 
7.56-7.70 (m, 2H, Ar); 7.80-7.93 (m, 2H, H-vinyl, NH); 8.12 (s, 1H, Ar); 10.00 (br s, 1H) ppm. 13C 
NMR: δ 168.96, 148.33, 147.73, 143.18, 134.33, 133.73, 133.02, 129.96, 128.58, 127.41, 126.08, 
125.63, 124.10, 122.02, 119.82, 111.28, 109.74; 55.45; 55.33; 46.15 ppm. Anal. C21H20N4O5S) 
Calc%: C 57.26, H 4.58, N 12.72, S 7.28. Found%: C 57.21, H 4.73, N 12.74, S 7.37. 
4.4.4. (3Z)-N-(2-oxo-(3-(thiophen-2-ylmethylene)indolin-5-yl)methanesulfonamide (14). The 
residual material was purified by crystallization from EtOH, affording 14 as the Z-isomer (48 mg, 
0.15 mmol, 38% yield): mp 185-187°C. 1H NMR: δ 2.94 (s, 3H, Me); 6.73-6.90 (m, 1H, Ar); 7.00-
7.36 (m, 2H, Ar); 7.54 (s, 1H, Ar); 7.79-8.29 (m, 3H, H-vinyl, Ar); 9.38 (br s, 1H); 10.57 (br s, 1H, 
NH) ppm. 13C NMR: δ 167.09, 137.83, 137.66, 137.01, 134.27, 131.29, 128.47, 127.25, 124.77, 
123.46, 121.27, 114.54, 109.60, 38.26 ppm. Anal. (C14H12N2O3S2) Calc%: C 52.48, H 3.78, N 8.74, 
S 20.02. Found%: C 52.64, H 3.66, N 8.89, S 20.24.  
4.4.5. (3E)-N-(2-oxo-(3-(1-methyl-1H-imidazol-2yl)methylene)indolin-5-yl)methanesulfonamide 
(15). The residual material was purified by crystallization from EtOH, affording 15 as the E-isomer 
(51 mg, 0.16 mmol, 40% yield): mp 197-199°C. 1H NMR: δ 2.99 (s, 3H, Me); 3.90 (s, 3H, NMe); 
6.82 (d, 1H, J = 8.2 Hz, Ar); 7.11 (dd, 1H, J = 2.0, 8.2 Hz, Ar); 7.34 (s, 1H, Ar); 7.38 (s, 1H, Ar); 
7.52 (s, 1H, H-vinyl); 9.37 (d, 1H, J = 2.0 Hz, Ar); 9.42 (br s, 1H); 10.57 (br s, 1H, NH) ppm. 13C 
NMR: δ 168.92, 139.65, 136.81, 135.45, 131.89, 131.56, 127.46, 123.59, 123.24, 121.13, 117.67, 
110.02, 45.07, 38.20 ppm. Anal. (C14H14N4O3S) Calc%: C 52.82, H 4.43, N 17.60, S 10.07. 
Found%: C 52.78, H 4.73, N 17.52, S 10.25.  
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4.4.6. (3Z)-N-(2-oxo-3-((1H-imidazol-5yl)methylene)indolin-5-yl)methanesulfonamide (16). The 
residual material was purified by crystallization from EtOH, affording 16 as the Z-isomer (55 mg, 
0.18 mmol, 45% yield): mp 205-207°C. 1H NMR: δ 2.94 (s, 3H, Me); 6.87 (d, 1H, J = 8.1 Hz, Ar); 
7.05 (dd, 1H, J = 1.7, 8.1 Hz, Ar); 7.50 (d, 1H, J = 1.7 Hz, Ar); 7.72 (s, 1H, Ar); 7.83 (s, 1H, Ar); 
8.03 (s, 1H, H-vinyl); 9.43 (br s, 1H); 11.02 (br s, 1H, NH) ppm. 13C NMR: δ 170.04, 139.14, 
137.77, 131.18, 127.85, 125.79, 123.73, 123.11, 122.29, 114.14, 110.22, 109.17, 38.27 ppm. Anal. 
(C13H12N4O3S) Calc%: C 51.31, H 3.97, N 18.41, S 10.54. Found%: C 51.44, H 4.05, N 18.29, S 
10.37.  
4.5. 5-amino-1,3-dihydro-2H-indol-2-one (17). The commercial 5-nitroindolin-2-one (1.00 g, 5.61 
mmol) was hydrogenated in EtOH (70 mL) in the presence of 10% Pd-C (315 mg, 2.97 mmol) for 4 
h. Then the catalyst was filtered off through Celite, the Celite rinsed with additional EtOH and the 
solution was evaporated, to give 17 as a brown solid (698 mg, 4.71 mmol, 84% yield). 1H NMR 
(CD3OD): δ 3.43 (s, 2H, CH2); 6.63-6.65 (m, 2H, Ar); 6.73-6.74 (m, 1H, Ar) ppm. Anal. 
(C8H8N2O) Calc%: C 64.85, H 5.44, N 18.91; Found%: C 65.03, H 5.49, N 18.83. 
 
4.6. 1-(4-(methylthio)phenyl)-3-(2-oxoindolin-5-yl)urea (18). To a solution of 5-amino-1,3-dihydro-
2H-indol-2-one 17 (148 mg, 1.0 mmol) in 10 mL DCM/MeOH (9:1), 1-isocyanato-4-
(methylsulfanyl)benzene (182 mg, 1.1 mmol) was added slowly at 10 °C. The mixture was stirred at 
the room temperature for 4 h. Solid product 18 was separated out from the mixture. It was filtered, 
washed with DCM, and air dried. (330 mg, 0.96 mmol, 96% yield): mp 212-214C. 1H NMR: δ 
2.43 (s, 3H, SMe); 3.52 (s, 2H, CH2); 6.72 (d, 1H, J = 8.2 Hz, Ar); 7.12-7.23 (m, 3H, Ar); 7.37 (s, 
1H, Ar); 7.41 (d, 2H, J = 8.8 Hz, Ar); 8.48 (br s, 1H); 8.62 (br s, 1H); 10.24 (br s, 1H, NH) ppm. 
13C NMR: δ 167.93, 158.66, 145.19, 142.75, 133.57, 129.87, 128.45, 127.67, 126.25, 113.33, 
109.09; 108.90; 36.71; 15.10 ppm. Anal. (C16H15N3O2S) Calc%: C 61.32, H 4.82, N 13.41, S 10.23; 
Found%: C 61.05, H 4.67, N 13.23, S 10.23. 
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4.7. N-(2-oxoindolin-5-yl)methanesulfonamide (19). To a stirred solution of 5-amino-2-oxindole 17 
(148 mg, 1.00 mmol) in H2O (10 mL) was added MsCl (137 mg, 1.2 mmol) at RT; stirring was 
continued at room temperature until TLC analysis shows disappearance of the starting material. 
Then the solution was evaporated to dryness. The residual material was diluted with MeOH and the 
solid product was filtered out from the mixture, washed with Et2O, and air dried. (19). (86 mg, 0.38 
mmol, 38% yield): mp 196-198°C. 1H NMR: δ 2.88 (s, 3H, Me); 3.47 (s, 2H, CH2); 6.77 (d, 1H, J = 
8.2 Hz, Ar); 7.04 (d, 1H, J = 8.2 Hz, Ar); 7.09 (s, 1H, Ar); 9.37 (br s, 1H); 10.37 (br s, 1H, NH) 
ppm. 13C NMR: δ 169.74, 135.61, 133.17, 131.18, 126.85, 123.51, 114.84, 112.82, 40.73, 37.41 
ppm. Anal. (C9H10N2O3S) Calc%: C 47.78, H 4.45, N 12.38, S 14.17; Found%: C 47.91, H 4.68, N 
12.51, S 14.28. 
 
4.8. 2 -́chloro-N-(2-oxo-2,3-dihydro-1H-indol-5-yl)acetamide (20). To a stirred solution of 5-
amino-2-oxindole 17 (122 mg, 0.82 mmol) in acetone (5 mL) and DMF (1.2 mL), cooled at 0°C, 
was added dropwise 2-chloroacetyl chloride (93 mg, 0.82 mmol). The reaction mixture was stirred 
at RT for additional 3 h, then the solvent was evaporated affording derivative 20, which was used 
without further purification (180 mg, 0.80 mmol, 98% yield). 1H NMR: δ 3.47 (s, 2H, CH2); 4.21 (s, 
2H, CH2Cl); 6.73-6.78 (m, 1H, Ar); 7.33 (d, 1H, J = 8.2 Hz, Ar); 7.49 (s, 1H, Ar); 10.15 (br s, 1H, 
NH); 10.33 (br s, 1H, NH) ppm. 13C NMR: δ 175.92, 163.90, 139.70, 132.22, 125.95, 118.82, 
116.61, 108.73, 43.36, 35.90 ppm. Anal. (C10H9ClN2O2) Calc%: C 53.47, H 4.04, N 12.47. 
Found%: C 53.67, H 4.19, N 12.59.  
4.9. 2-((3,4-dimethoxybenzyl)amino)-N-(2-oxoindolin-5-yl)acetamide (21). A solution of K2CO3 
(1.19 g, 8.61 mmol) in CH3CN (8 mL), heated at 80°C, was mixed with a solution of compound 20 
(879 mg, 3.91 mmol) in DMF (1.3 mL) and with a solution of 3,4-dimethoxybenzylamine (654 mg, 
3.91 mmol) in CH3CN (2 mL). The suspension was stirred at 80°C for 12 h, then the potassium 
carbonate was filtered off and the solvent removed. The residue was diluted with CH2Cl2 and 
washed with water and brine. The organic layer was dried and concentrated. 
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The crude product was purified by crystallization from AcOEt/n-hexane, affording compound 21 
(462 mg, 1.30 mmol, 33 % yield) as a yellow solid. 1H NMR (CDCl3): δ 3.52 (s, 2H, CH2); 3.78 (s, 
2H, CH2); 3.81 (s, 2H, CH2); 3.86 (s, 3H, OMe); 3.88 (s, 3H, OMe); 6.76-7.93 (m, 4H, Ar); 7.22 (d, 
1H, J = 8.6 Hz, Ar); 7.58 (s, 1H, Ar); 8.02 (br s, 1H, NH); 9.18 (br s, 1H, NH) ppm. 13C NMR 
(CDCl3): δ 178.05, 169.00, 149.13, 148.86, 139.07, 132.92, 129.16, 125.05, 123.00, 122.55, 120.45, 
111.93, 110.66, 56.94, 56.23, 53.70, 51.80, 36.56 ppm. Anal. (C19H21N3O4) Calc%: C 64.21, H 
5.96, N 11.82. Found%: C 63.97, H 5.59, N 11.59. 
 
4.10. Indolin-2-one (22). Iron chips (1.6 g, 29.40 mmol) were added in one portion to commercial 
2-nitrophenylacetic acid (2.0 g, 11.04 mmol) in of glacial acetic acid (25 mL). The resulting 
mixture was heated to 100 °C for 4 h, then concentrated to dryness, sonicated in AcOEt and filtered 
to remove the insolubles. The filtrate was washed twice with 1 N HCl, H2O, brine, dried over 
anhydrous sodium sulfate and concentrated, affording compound 22. (1.40 g, 10.49 mmol, 95% 
yield): mp 92-94°C. 1H NMR (CDCl3): δ 3.56 (s, 2H, CH2); 6.90 (d, 1H, J = 7.7 Hz, Ar); 6.98-7.06 
(m, 1H, Ar); 7.19-7.26 (m, 2H, Ar); 8.95 (br s, 1H) ppm. 13C NMR (CDCl3): δ 179.25, 143.38, 
128.54, 125.98, 125.12, 122.93, 110.66; 37.10 ppm. Anal. (C8H7NO2) Calc%: C 72.16, H 5.30, N 
10.52; Found%: C 72.32, H 5.35, N 10.48. 
 
4.11. 2-oxoindoline-5-sulfonyl chloride (23). Chlorosulfonic acid (27 mL, 408 mmoli) was slowly 
added dropwise to indolin-2-one 23 (13.3 g, 100 mmol). The reaction temperature was maintained 
below 30 °C during the addition. Later the reaction mixture was stirred at rt for 1.5h, and then at 
68°C for 1h, cooled, and poured carefully into water. The precipitate formed was collected by 
vacuum filtration, washed with H2O and dried in a vacuum oven to give compound 23, which was 
used without further purification (3.02 g, 13.03 mmol, 98% yield): mp 180-185°C. 1H NMR: δ 3.46 
(s, 2H, CH2); 6.74 (d, 1H, J = 7.7 Hz, Ar); 7.42-7.46 (m, 2H, Ar); 10.48 (br s, 1H) ppm. 13C NMR: 
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δ 175.89, 143.68, 139.71, 124.55, 121.32, 107.39; 35.16 ppm. Anal. (C8H6ClNO3S) Calc%: C 
41.48, H 2.61, N 6.05, S 13.84; Found%: C 41.57, H 2.72, N 6.14, S 13.92. 
 
4.12. N-(3,4-dimethoxybenzyl)-2-oxoindoline-5-sulfonamide (24). To a stirred solution of 2-
oxoindoline-5-sulfonyl chloride 23 (530 mg, 2.29 mmol) in EtOH (10 mL) was added a solution 
3,4-dimethoxybenzylamine (418 mg, 2.50 mmol) in EtOH (2 mL). The suspension was stirred at 
RT for 4 h, then the mixture was concentrated and the solid collected by vacuum filtration. The 
residual material was purified by crystallization from MeOH, affording compound 24 (664 mg, 1.83 
mmol, 80% yield): mp 227-232°C. 1H NMR: δ 3.52 (s, 2H, CH2); 3.65 (s, 3H, OMe); 3.69 (s, 3H, 
OMe); 3.88 (d, 1H, J = 6.2 Hz, CH2); 6.68-6.82 (m, 3H, Ar); 6.90 (d, 1H, J = 8.1 Hz, Ar); 7.51 (s, 
1H, Ar); 7.60 (d, 1H, J = 8.1 Hz, Ar); 7.89 (br t, 1H, J = 6.2 Hz); 10.76 (br s, 1H) ppm. 13C NMR: δ 
168.20, 148.35, 147.75, 143.02, 134.39, 133.50, 128.04, 127.67, 126.08, 122.41, 111.89, 111.31, 
109.46; 55.49; 55.20; 46.10; 34.10 ppm. Anal. (C17H18N2O5S) Calc%: C 56.43, H 5.01, N 7.73, S 
8.85; Found%: C 56.26, H 5.32, N 7.80, S 8.92. 
 
4.13. Molecular descriptor calculation. Molecular descriptors related to ADME and drug-likeness 
properties of the investigated compounds were calculated by using publicly available software. In 
particular, the following descriptors: MW, nHBA, nHBD, nRotB, nRotBt, and Lipinski Failures 
were calculated with PaDEL Descriptor [20]; LogP, LogD, TPSA, and pKa were calculated with 
ChemAxon MarvinSketch 6.3.0 [21]; CNS MPO was calculated according to Wager et al. [22]  
 
5. In vitro biological studies 
5.1. Cell lines 
The human AsPC1 cell line derived from human pancreatic adenocarcinoma. Cells were grown in 
RPMI-1640 with 10% fetal bovine serum, 1% glutamine and 1% penicillin–streptomycin (Sigma-
Aldrich). Cells were cultured in Petri dishes at 37 °C in 5% CO2 and 95% air. U118MG and 
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ANGM-CSS cell lines, derived from human glioblastoma (ATCC, Manassas, VA, USA and 
IRCCS-CASA, Sollievo Della Sofferenza Hospital, San Giovanni Rotondo, FG, Italy), were  both 
cultured in DMEM:HAMS F12 (1:1) (Sigma-Aldrich) supplemented with 2 mM of L-glutamine 
(Sigma Aldrich), 10% Foetal Bovine Serum (FBS, Sigma-Aldrich), 100 units/ml penicillin and 
100µg/ml streptomycin (P/S) in tissue culture flasks at 37°C in a humidified atmosphere of 5% 
CO2. 
 
5.1.1. Cell proliferation assay on ASPC1  
Cells were plated in 12-well sterile plastic plates, allowed to attach for 24 h, and then treated in 
duplicate with indicated compounds at 10 µM. After 72 h, the number of viable cells was assessed 
by manual cell counting. Changes in cell growth were expressed as a percentage relative to cells 
treated with DMSO (control). 
 
 
5.1.2. Z’Lyte assay on selected Kinases. The assay was performed by Invitrogen corporation on 
AKT1 (PKB alpha), PDK1 direct, CHK1, GSK3A and GS3KB as reported below: (AKT1)The 2X 
AKT1 (PKB alpha) / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 
mM MgCl2, 1 mM EGTA. The final 10 μL kinase reaction consists of 1.15 - 25 ng AKT1 (PKB 
alpha) and 2 μM Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM 
EGTA. After the 1 hour kinase reaction incubation, 5 μL of a 1:2048 dilution of Development 
Reagent A is added. (PDK1 Direct) The 2X PDK1 Direct / Ser/Thr 07 mixture is prepared in 50 
mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μL 
kinase reaction consists of 7.36 - 38.7 ng PDK1 Direct and 2 μM Ser/Thr 07 in 50 mM Tris / 
HEPES pH 8.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 h kinase 
reaction incubation, 5 μL of a 1:32768 dilution of development reagent A is added. CHEK1 
(CHK1): The 2X CHEK1 (CHK1) / Ser/Thr 19 mixture is prepared in 50 mM HEPES pH 7.5, 
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0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.04 - 
35 ng CHEK1 (CHK1) and 2 μM Ser/Thr 19 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM 
MgCl2, 1 mM EGTA. After the 1 h Kinase Reaction incubation, 5 μL of a 1:256 dilution of 
Development Reagent A is added. GSK3A (GSK3 alpha): The 2X GSK3A (GSK3 alpha) / Ser/Thr 
09 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. 
The final 10 μL Kinase Reaction consists of 0.21 - 1.69 ng GSK3A (GSK3 alpha) and 2 μM 
Ser/Thr 09 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 
hour Kinase Reaction incubation, 5 μL of a 1:512 dilution of Development Reagent A is added. 
GSK3B (GSK3 beta): The 2X GSK3B (GSK3 beta) / Ser/Thr 09 mixture is prepared in 50 mM 
HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction 
consists of 0.17 - 0.88 ng GSK3B (GSK3 beta) and 2 μM Ser/Thr 09 in 50 mM HEPES pH 7.5, 
0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL 
of a 1:512 dilution of Development Reagent A is added. 
 
5.1.3. Protein kinase profiling. Effect of the indicated compounds on the activity of various 
kinases was assessed by SelectScreen Kinase Profiling Service (Invitrogen-Life Technologies, 
Paisley, UK). Assays were performed using 1uM of compound 3 and ATP concentration as 
indicated in the corresponding table.  
 
5.1.4. Cell proliferation assay on ANGM-CSS and U118MG 
Cells were cultured up to about 80% confluence in culture medium and 24 hours before the 
experiment, cells were seeded onto 96-well plates at a density per well of 103 for U118MG and 
3x103 for ANGM-CSS (only for U118MG it was necessary to pre-coat every well with gelatine 1% 
from porcine skin, Sigma–Aldrich) . After 24 hours to allow cell attachment, the medium was 
replaced in each 96-well plate and the cells were treated for 72h, 96h, 120h and 144h with G51 
compound (40M, 20M, 10M, 5M and 2,5M), vehicle (DMSO 0.1%) or control (no-
24 
 
treatment). At the end of each treatments cell viability was assessed using the Cell Proliferation 
Reagent WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolium]-1,3-benzene 
disulphonate) (Roche, Mannheim, Germany) based on the cellular cleavage of the WST-1 to 
formazan. WST-1 was added at 1/10 of the total volume and after 60 min of incubation at 37°C, the 
absorbance was measured at 450 nm with a multiplate reader (Enspire; PerkinElmer, Wellesley, 
MA, USA).  
 
5.1.5. GSC isolation from ANGM-CSS cells  
To obtain the GSC subpopulation, approximately 2.0 x 106 ANGM-CSS cells were suspended in 1 
mL of a defined serum-free Neural Stem Cell (NSC) medium [33]. After 5-6 days of culture, GSCs 
(called “neurospheres”) were collected, suspended in NSC medium, dissociated into single cells and 
plated for the assays. The method accuracy for GSC isolation was verified in previous 
experiments[19, 33]. For the long-term treatment of cells, NSC or complete medium containing 
drugs was replaced every two to three days. 
 
5.1.6. Cell proliferation assays on GSCs  
GSCs were seeded at a density of 3 x 104 cells/well in 24 well-plate, and then treated from one to 
seven days with fresh growth medium containing different concentrations of compound 3  (0.1 nM- 
100 µM). Following the treatment period, GSCs were collected and transferred in 96 well-plate, and 
cell proliferation was determined using the MTS assay according to manufacturer's instruction. The 
absorbance of formazan at 490 nM was measured in a colorimetric assay with an automated plate 
reader (Victor Wallac 2, Perkin Elmer). The results were calculated by subtracting the mean 
background from the values obtained from each evaluation and were expressed as the percentage of 
the control (untreated cells). Sigmoid dose-response curve was generated, from which the IC50 
values were derived. 
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5.1.7. Annexin V and 7-AAD staining in ANGM-CSS cells and in GSCs  
Dual staining with Annexin V coniugated to fluorescein-isothiocyanate (FITC) and 7-amino-
actinomysin (7-AAD) was performed using the commercially available kit (Muse Annexin V and 
Dead Cell Kit; Merck KGaA, Darmstadt, Germany). ANGM-CSS cells or GSCs were treated with 
DMSO (control) or compound 3 (1 µM)  for 72 h or seven days, respectively. At the end of the 
treatment periods, the percentages of living, apoptotic and dead cells were acquired and analyzed by 
Muse™ Cell Analyzer as previously described[19]. 
 
5.1.8. Cell cycle analysis in ANGM-CSS cells and in GSCs. The measurement of the percentage 
of cells in the different cell phases was performed using the Muse™ Cell Analyzer (Merck KGaA, 
Darmstadt, Germany). Briefly, U87MG or GSCs were treated with DMSO or compound 3 (1 µM), 
for 72 h or seven days, respectively. Cells were collected and centrifuged at 300 x g for 5 minutes. 
The pellets were washed with PBS and suspended in 100 µl of PBS, and cells were slowly added to 
1 ml of ice cold 70% ethanol and maintained o/n at –20 °C. Then, a cell suspension aliquot 
(containing at least 2x105 cells) was centrifuged at 300 x g for 5 minutes, washed once with PBS 
and suspended in the fluorescent reagent (Muse™ Cell Cycle reagent) [34]. 
 
5.1.9. RNA extraction and Real Time PCR analysis in GSCs  
GSCs were treated with DMSO (control), or different concentrations of compound 3 (1 nM-1µM) 
for seven days. At the end of treatments, cells were collected, and total RNA was extracted using 
Rneasy® Mini Kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. cDNA 
synthesis was performed with 500 ng of RNA using i-Script cDNA synthesis kit (BioRad, Hercules, 
USA) following manufacturer’s instructions. RT-PCR reactions consisted of 25 µL Fluocycle® II 
SYBR® (Euroclone, Milan, Italy), 1.5 µL of both 10 µM forward and reverse primers, 3 µL cDNA, 
and 19 µL of H2O. All reactions were performed for 40 cycles using the following temperature 
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profiles: 98 °C for 30 seconds (initial denaturation); T °C (see Table S2) for 30 seconds (annealing); 
and 72 °C for 3 seconds (extension) [33]. 
 
5.1.10. Quantitation of the occupied area and the cellular processes of neurospheres  
GSCs were plated in complete growth medium (day 0) and treated for the indicated days with 
compound 3. Photographs of the neurospheres were taken at days 0, 7, and 21. Three different wells 
were analysed for each condition, and 15 images of each well were captured[19, 33]. The response 
of the cultures to the various treatments was quantified by measuring the area occupied by 
neurospheres that had formed, using the Image J program (version 1.41; Bethesda, MD, USA). The 
cellular processes extending from the six to eight differentiating neurospheres per condition in three 
independent experiments were evaluated.  
 
5.1.11. Neurosphere formation assay  
The ability of ANGM-CSS to initiate neurosphere formation were assessed by harvesting, washing, 
and resuspending monolayer cells in serum-free NSC medium. Cells were seeded into 96-well at 
2x104 cells/well and incubated with DMSO (0.5%, control) or compound 3 (1µM) for 9 days 
without disturbing the plates, and without replenishing the medium. At the end of the treatment 
period, pictures of the neurospheres were taken. Three different wells were analysed for each 
condition and 3 images of each well were captured. The number and the diameter of the newly 
formed neurosphere were estimated using the Image J program (version 1.41; Bethesda, MD, USA). 
 
6. Statistical analysis  
All the experiments were performed in duplicate and repeated three times. ASPC1 data were 
expressed as mean values ± S.D. and analyzed by Student’s t test; the level of significance was set 
at P < 0.05. 
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The nonlinear multipurpose curve-fitting program Graph-Pad Prism (GraphPad Software Inc., San 
Diego, CA) was used for data analysis and graphic presentations. All data are presented as the mean 
± SEM. Statistical analysis was performed by one-way analysis of variance (ANOVA) with 
Bonferroni’s corrected t-test for post-hoc pair-wise comparisons. P<0.05 was considered 
statistically significant. The parameter of GI50 was calculated as the molar concentration of the 
tested compound evoking a half reduction in cell viability. 
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Captions 
 
Figure 1. Structures of PI3K/Akt/mTOR inhibitors  
  
Figure 2. Histograms represent cell viability on ANGM-CSS cell line (A) and U118MG (B) 
after 72, 96, 120 and 144 h of no treatment (Control), treatment with several concentrations of 
compound 3 (2.5, 5, 10, 20, 40 M) or vehicle (DMSO 0.1 %). The GI50 values recorded at each 
time, are also shown.  Vertical bars indicate the standard error. The asterisk (*) indicates a value of 
viability significantly different from the value of viability of the corresponding control group (*P < 
0.05; **P < 0.01; ***P < 0.001).  
Figure 3. Compound 3 induced apoptosis and cell cycle arrest. A) ANGM-CSS cells were 
treated for 72 h with DMSO (control), or 3 (10 µM). At the end of the treatment period, the cells 
were collected, and the level of phosphatidylserine externalisation was evaluated using the Annexin 
V-staining protocol. B) The data are expressed as the percentage of apoptotic cells (the data for the 
early-stage apoptotic cells shown in white, while the ones for the late-stage apoptotic/necrotic cells 
shown in grey) versus the total number of cells. C, D) ANGM-CSS were treated as in A; at the end 
of the treatment period, cells were collected and the cell cycle was analysed. The data were 
expressed as percentage of cell in the different phases (G0/G1, G2 or S) versus total cell number. 
All the data shown represent the mean ± SEM of three different experiments. The significance of 
the differences was determined with a one-way ANOVA with Bonferroni post-test: *p<0.05, 
**p<0.01, *** p<0.001 vs. control.  
Figure 4. ANGM-CSS-derived GSCs were incubated in Neural Stem Cells (NSC) medium with 
the indicated concentrations of 3 for three (A) or seven days (A,B). At the end of the treatment 
periods, cell proliferation was measured using the MTS assay. The data are expressed as a 
percentage with respect to that of untreated cells (control), and are the mean values ± SEM of three 
independent experiments, each performed in duplicate. IC50 values after 7 days of treatment were 
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calculated from sigmoid dose-response curve (B). The significance of the differences was 
determined with a one-way ANOVA with Bonferroni post-test: *** p<0.001 vs. control. 
Figure 5. GSCs were treated for 7 days with NSC medium containing DMSO (control), or 1µM 
3. At the end of treatments, the cells were collected and the degree of phosphatidylserine 
externalisation was evaluated using the Annexin V protocol. B) The data were expressed as the 
percentage of apoptotic cells (early-apoptotic in white, late-apoptotic/necrotic in grey) relative to 
the total number of cells. C, D) Cell cycle analysis at the end of treatment. The data were expressed 
as percentage of cell in the different phases (G0/G1, G2 or S) versus total cell number. All the data 
shown represent the mean ± SEM of three different experiments. The significance of the differences 
was determined with a one-way ANOVA with Bonferroni post-test: *p<0.05, ** p<0.01 vs. control. 
Figure 6. GSCs were treated for 7 days with complete NSC medium containing DMSO 
(control), or 3 (1M). (A) Representative cell micrographs after 7 days of treatment were shown. 
(B) The area of the culture plates occupied by the spheres and (C) the length of cellular processes 
were scored after 7 days of treatment. The counts represent the mean values ± SEM of two 
independent experiments. (D) GSCs were treated as in A. At the end of treatments, Real time RT-
PCR was performed using primer for  the stem cell markers CD133 and Nestin, the oligodendrocyte 
marker Olig, the neuronal marker MAP and for the astrocyte marker GFAP. Data were expressed as 
fold of change vs the levels of the control (set to 1) and are the mean values ± SEM of three 
different experiments. The significance of the differences was determined with a one-way ANOVA 
with Bonferroni post-test:  ***p < 0.001 vs control. 
Figure 7. Effects of 3 on the formation of GSCs. Adherent ANGM-CSS cells were switched 
to NSC medium, and cells were allowed to growth for 9 days, in the absence or in the presence of 1 
µM 3 (A) Representative picture of ANGM-CSS neurospheres after 9 days of  incubation. The 
number of the newly formed spheres (B) and the mean diameter (C) were scored using ImageJ. 
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Data represent the mean ± SEM of three pictures of two independent experiments. The significance 
of the differences was determined with a one-way ANOVA with Bonferroni post-test: ***p<0.001 
vs control. 
Scheme 1a. Reagents and conditions. a) (methylthio)phenyl-isocyanate, DCM/MeOH, 10°C–
rt, 3–4 h; b) Aryl-carbaldehyde, EtOH, piperidine, 110°C, 12 h; c) Oxone, MeOH/THF, rt, 12 h; d) 
MsCl, H2O, rt; e) ClCH2COCl, H2O, rt, 3h; f) 3,4-Dimethoxybenzylamine, K2CO3, DMF, CH3CN, 
82°C, 12 h;  
Scheme 2a. Reagents and conditions. a) Fe, AcOH, reflux, 2 h; b) ClSO2OH, rt, 1.5h  68°C, 
1 h; c) 3,4-dimethoxybenzylamine, EtOH, rt, 4 h; d) Aryl-carbaldehyde, EtOH, pirrolidine, 110°C. 
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Table 1. Molecular descriptors related to ADME and drug-likeness properties of the investigated 
compounds.  
 
 
MW = molecular weight; nHBA: number of Hydrogen Bond Acceptors; nHBD: number of Hydrogen Bond Donors; 
nRotB: Rotational Bonds; nRotBt: terminal Rotational bonds; LogP = partition coefficient; LogD = distribution 
coefficient; TPSA = topological polar surface area; pKa = most basic center; LF (Lipinski failures) =  number of 
deviations from Lipinski’s rule; CNS MPO = druglikeness central nervous system multiparameter optimization;  aRef. 
10. bCalculated with PaDEL descriptors; cCalculated with MarvinSketch; dCalculated according to ref.13 
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Table 2. Cytotoxicity of compounds 1-16 on ASPC1 cell proliferation assessed by cell counting at 
10 µM after 72 h (% viable cells compared to control). Data were expressed as mean values ± SEM 
(n=3). 
 
 
 
Compd Cell Counting ± S.D. Compd Cell Counting ± S.D. 
1 82.04 ± 3.44 9 90.57 ± 3.88 
2 82.34 ± 2.87 10 82.21 ± 9.43 
3* 68.14 ± 2.23 11 84.18 ± 6.67 
4 86.75 ± 0.76 12 84.50 ± 4.75 
5 77.29 ± 9.93 13 n.d. 
6 95.13 ± 3.46 14* 68.06 ± 11.08 
7 82.94 ± 1.42 15 96.23 ± 3.55 
8 93.88 ± 5.53 16* 73.83 ± 11.19 
 * reduction of the proliferative activity of around 30% 
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Table 3. Results from SelectScreen Kinase Profiling Service (Invitrogen-LifeTechnologies) of 3 
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38 
 
 
Figure 3. 
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Scheme 2a. 
 
 
